|
CA2645227A1
|
|
Hydrazido derivatives of hyaluronic acid
|
|
CA2574644A1
|
|
Porous plasma protein matrices and methods for preparation thereof
|
|
US2006019389A1
|
|
Porous plasma protein matrices and methods for preparation thereof
|
|
EP1592373A2
|
|
Freeze-dried fibrin matrices and methods for preparation thereof
|
|
AU2003283785A1
|
|
Bone enhancing composite
|
|
IL156495D0
|
|
Use of fgfr3 antagonists for treating t cell mediated diseases
|
|
AU2003224406A1
|
|
Fgf variants and methods for use thereof
|
|
IL154559D0
|
|
Modulators of growth factor receptor phosphorylation and methods of using same
|
|
IL154208D0
|
|
Plasma protein matrices and methods for preparation thereof
|
|
IL153699D0
|
|
Bone graft composite
|
|
AU2002353462A1
|
|
Zinc finger proteins, polynucleotides encoding same and antibodies thereto
|
|
AU2002334355A1
|
|
Protein tyrosine kinase inhibitors
|
|
IL159920D0
|
|
Plasma protein matrices and methods for their preparation
|
|
IL159177D0
|
|
Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
|
|
IL148293D0
|
|
Modulators of growth factor receptor phosphorylation and methods of using same
|
|
AU2002217408A1
|
|
Chondrocyte-specific and non-specific elements in the fgfr-3 promoter region
|
|
WO0224722A2
|
|
Crystalline fgf9 dimer and methods of use
|
|
IL145329D0
|
|
Protein tyrosine kinase inhibitors
|
|
IL144446D0
|
|
Plasma protein matrices and methods for their preparation
|
|
IL142118D0
|
|
Method and composition for treatment of skeletal dysplasias
|
